08:00 , Nov 5, 2012 |  BioCentury  |  Strategy

Racing to rebuild AZ

AstraZeneca plc's new CEO Pascal Soriot has not yet detailed his vision for the company, but comments last month on his first call with investors coupled with an early move to halt the company's planned...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Rigel, AstraZeneca deal

Rigel granted AstraZeneca exclusive, worldwide rights to develop and commercialize inhaled Janus kinase (JAK) inhibitor R256. The compound is in preclinical testing to treat moderate to severe chronic asthma. AstraZeneca is responsible for further...
07:00 , Jun 25, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) jumped $1.23 (45%) to $3.97 on Friday after resubmitting an NDA to FDA for Adasuve Staccato loxapine to treat agitation in patients with schizophrenia or bipolar disorder. In May, FDA...
00:47 , Jun 20, 2012 |  BC Extra  |  Company News

AstraZeneca, Rigel in asthma deal

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive, worldwide rights to develop and commercialize inhaled Janus kinase (JAK) inhibitor R256. The compound is in preclinical testing to treat moderate to severe chronic asthma....